Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case

Drug Discov Today. 2013 Oct;18(19-20):1014-24. doi: 10.1016/j.drudis.2012.10.011. Epub 2012 Nov 3.

Abstract

In this study, the screening collections of two major pharmaceutical companies (AstraZeneca and Bayer Pharma AG) have been compared using a 2D molecular fingerprint by a nearest neighborhood approach. Results revealed a low overlap between both collections in terms of compound identity and similarity. This emphasizes the value of screening multiple compound collections to expand the chemical space that can be accessed by high-throughput screening (HTS).

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Discovery / methods
  • Drug Discovery / trends*
  • Drug Evaluation, Preclinical / methods
  • Drug Evaluation, Preclinical / trends
  • Drug Industry / methods
  • Drug Industry / trends*
  • High-Throughput Screening Assays / methods
  • High-Throughput Screening Assays / trends*
  • Humans
  • Small Molecule Libraries / chemistry*

Substances

  • Small Molecule Libraries